12-Month Lobbying Summary - Consultant

Details Regarding the Identified Subject Matter

Subject matters	Details	Categories
Federal-Provincial Relations, Health, Research and Development	Bill C-64, An Act respecting pharmacare (Pharmacare Act)	Legislative Proposal, Bill or Resolution
Health, Research and Development, Science and Technology	Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food & Drug Act.	Legislative Proposal, Bill or Resolution
International Trade	Free trade treaty agreement as it relates to the Canada US Free Trade Agreement (CUSMA) and free trade negotiations as it relates to Columbia, India, and the European Union.	Policies or Program
Health, Intellectual Property	Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly's business.	Regulation
Health, Intellectual Property, Science and Technology	Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.	Legislative Proposal, Bill or Resolution
Health, Industry, Intellectual Property	Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.	Regulation
Industry, Intellectual Property, Taxation and Finance	Patented Medicines Prices Review Board (PMPRB) proposed regulations, in regards to pharmaceutical pricing policy.	Policies or Program
Health, Science and Technology	The government's Science and Technology Strategy potential policies & programs pertaining to the biopharmaceutical industry.	Policies or Program

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food & Drug Act.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Free trade treaty agreement as it relates to the Canada US Free Trade Agreement (CUSMA) and free trade negotiations as it relates to Columbia, India, and the European Union.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly's business.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicines Prices Review Board (PMPRB) proposed regulations, in regards to pharmaceutical pricing policy.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	The government's Science and Technology Strategy potential policies & programs pertaining to the biopharmaceutical industry.	Policies or Program

  Subject matters in previous versions

  • Economic Development
  • Health
  • Industry
  • Intellectual Property
  • International Trade
  • Research and Development
  • Science and Technology
  • Taxation and Finance

Government Institutions

• Federal Economic Development Agency for Southern Ontario (FedDev)
• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Indigenous Services Canada (ISC)
• Innovation, Science and Economic Development Canada (ISED)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Senate of Canada

• Government institutions in previous versions

  • Agriculture and Agri-Food Canada (AAFC)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Written communication
• Oral communication
• Arrange one or more meetings

ANDRE ALBINATI, Consultant (Business address and contact information)

Public offices held